갈메드 파마슈티컬스(GLMD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.48 (+2.05%), 시가총액 $0.00B, 52주 최저~최고 $0.47 ~ $2.33.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methi
갈메드 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
갈메드 파마슈티컬스의 현재 주가는 $3.48 (+2.05%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
갈메드 파마슈티컬스의 시가총액은 약 $0.00B입니다.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first